Cargando…

hapE and hmg1 Mutations Are Drivers of cyp51A-Independent Pan-Triazole Resistance in an Aspergillus fumigatus Clinical Isolate

Aspergillus fumigatus is a ubiquitous environmental mold that can cause severe disease in immunocompromised patients and chronic disease in individuals with underlying lung conditions. Triazoles are the most widely used class of antifungal drugs to treat A. fumigatus infections, but their use in the...

Descripción completa

Detalles Bibliográficos
Autores principales: Souza, Ana C. O., Ge, Wenbo, Wiederhold, Nathan P., Rybak, Jeffrey M., Fortwendel, Jarrod R., Rogers, P. David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10269825/
https://www.ncbi.nlm.nih.gov/pubmed/37140376
http://dx.doi.org/10.1128/spectrum.05188-22
_version_ 1785059258656620544
author Souza, Ana C. O.
Ge, Wenbo
Wiederhold, Nathan P.
Rybak, Jeffrey M.
Fortwendel, Jarrod R.
Rogers, P. David
author_facet Souza, Ana C. O.
Ge, Wenbo
Wiederhold, Nathan P.
Rybak, Jeffrey M.
Fortwendel, Jarrod R.
Rogers, P. David
author_sort Souza, Ana C. O.
collection PubMed
description Aspergillus fumigatus is a ubiquitous environmental mold that can cause severe disease in immunocompromised patients and chronic disease in individuals with underlying lung conditions. Triazoles are the most widely used class of antifungal drugs to treat A. fumigatus infections, but their use in the clinic is threatened by the emergence of triazole-resistant isolates worldwide, reinforcing the need for a better understanding of resistance mechanisms. The predominant mechanisms of A. fumigatus triazole resistance involve mutations affecting the promoter region or coding sequence of the target enzyme of the triazoles, Cyp51A. However, triazole-resistant isolates without cyp51A-associated mutations are frequently identified. In this study, we investigate a pan-triazole-resistant clinical isolate, DI15-105, that simultaneously carries the mutations hapE(P88L) and hmg1(F262del), with no mutations in cyp51A. Using a Cas9-mediated gene-editing system, hapE(P88L) and hmg1(F262del) mutations were reverted in DI15-105. Here, we show that the combination of these mutations accounts for pan-triazole resistance in DI15-105. To our knowledge, DI15-105 is the first clinical isolate reported to simultaneously carry mutations in hapE and hmg1 and only the second with the hapE(P88L) mutation. IMPORTANCE Triazole resistance is an important cause of treatment failure and high mortality rates for A. fumigatus human infections. Although Cyp51A-associated mutations are frequently identified as the cause of A. fumigatus triazole resistance, they do not explain the resistance phenotypes for several isolates. In this study, we demonstrate that hapE and hmg1 mutations additively contribute to pan-triazole resistance in an A. fumigatus clinical isolate lacking cyp51-associated mutations. Our results exemplify the importance of and the need for a better understanding of cyp51A-independent triazole resistance mechanisms.
format Online
Article
Text
id pubmed-10269825
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher American Society for Microbiology
record_format MEDLINE/PubMed
spelling pubmed-102698252023-06-16 hapE and hmg1 Mutations Are Drivers of cyp51A-Independent Pan-Triazole Resistance in an Aspergillus fumigatus Clinical Isolate Souza, Ana C. O. Ge, Wenbo Wiederhold, Nathan P. Rybak, Jeffrey M. Fortwendel, Jarrod R. Rogers, P. David Microbiol Spectr Research Article Aspergillus fumigatus is a ubiquitous environmental mold that can cause severe disease in immunocompromised patients and chronic disease in individuals with underlying lung conditions. Triazoles are the most widely used class of antifungal drugs to treat A. fumigatus infections, but their use in the clinic is threatened by the emergence of triazole-resistant isolates worldwide, reinforcing the need for a better understanding of resistance mechanisms. The predominant mechanisms of A. fumigatus triazole resistance involve mutations affecting the promoter region or coding sequence of the target enzyme of the triazoles, Cyp51A. However, triazole-resistant isolates without cyp51A-associated mutations are frequently identified. In this study, we investigate a pan-triazole-resistant clinical isolate, DI15-105, that simultaneously carries the mutations hapE(P88L) and hmg1(F262del), with no mutations in cyp51A. Using a Cas9-mediated gene-editing system, hapE(P88L) and hmg1(F262del) mutations were reverted in DI15-105. Here, we show that the combination of these mutations accounts for pan-triazole resistance in DI15-105. To our knowledge, DI15-105 is the first clinical isolate reported to simultaneously carry mutations in hapE and hmg1 and only the second with the hapE(P88L) mutation. IMPORTANCE Triazole resistance is an important cause of treatment failure and high mortality rates for A. fumigatus human infections. Although Cyp51A-associated mutations are frequently identified as the cause of A. fumigatus triazole resistance, they do not explain the resistance phenotypes for several isolates. In this study, we demonstrate that hapE and hmg1 mutations additively contribute to pan-triazole resistance in an A. fumigatus clinical isolate lacking cyp51-associated mutations. Our results exemplify the importance of and the need for a better understanding of cyp51A-independent triazole resistance mechanisms. American Society for Microbiology 2023-05-04 /pmc/articles/PMC10269825/ /pubmed/37140376 http://dx.doi.org/10.1128/spectrum.05188-22 Text en Copyright © 2023 Souza et al. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research Article
Souza, Ana C. O.
Ge, Wenbo
Wiederhold, Nathan P.
Rybak, Jeffrey M.
Fortwendel, Jarrod R.
Rogers, P. David
hapE and hmg1 Mutations Are Drivers of cyp51A-Independent Pan-Triazole Resistance in an Aspergillus fumigatus Clinical Isolate
title hapE and hmg1 Mutations Are Drivers of cyp51A-Independent Pan-Triazole Resistance in an Aspergillus fumigatus Clinical Isolate
title_full hapE and hmg1 Mutations Are Drivers of cyp51A-Independent Pan-Triazole Resistance in an Aspergillus fumigatus Clinical Isolate
title_fullStr hapE and hmg1 Mutations Are Drivers of cyp51A-Independent Pan-Triazole Resistance in an Aspergillus fumigatus Clinical Isolate
title_full_unstemmed hapE and hmg1 Mutations Are Drivers of cyp51A-Independent Pan-Triazole Resistance in an Aspergillus fumigatus Clinical Isolate
title_short hapE and hmg1 Mutations Are Drivers of cyp51A-Independent Pan-Triazole Resistance in an Aspergillus fumigatus Clinical Isolate
title_sort hape and hmg1 mutations are drivers of cyp51a-independent pan-triazole resistance in an aspergillus fumigatus clinical isolate
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10269825/
https://www.ncbi.nlm.nih.gov/pubmed/37140376
http://dx.doi.org/10.1128/spectrum.05188-22
work_keys_str_mv AT souzaanaco hapeandhmg1mutationsaredriversofcyp51aindependentpantriazoleresistanceinanaspergillusfumigatusclinicalisolate
AT gewenbo hapeandhmg1mutationsaredriversofcyp51aindependentpantriazoleresistanceinanaspergillusfumigatusclinicalisolate
AT wiederholdnathanp hapeandhmg1mutationsaredriversofcyp51aindependentpantriazoleresistanceinanaspergillusfumigatusclinicalisolate
AT rybakjeffreym hapeandhmg1mutationsaredriversofcyp51aindependentpantriazoleresistanceinanaspergillusfumigatusclinicalisolate
AT fortwendeljarrodr hapeandhmg1mutationsaredriversofcyp51aindependentpantriazoleresistanceinanaspergillusfumigatusclinicalisolate
AT rogerspdavid hapeandhmg1mutationsaredriversofcyp51aindependentpantriazoleresistanceinanaspergillusfumigatusclinicalisolate